RESEARCH DIGEST - DELTA SLEEP-INDUCING PEPTIDE - EVIDENCE APPRAISAL
DSIP, the delta sleep-inducing peptide, has been studied for slow-wave sleep for over forty years.
An evidence-appraisal digest of a nine-amino-acid peptide with a famous name, a few real findings, and one stubbornly missing reading: no one has found its receptor.
The short version
DSIP stands for delta sleep-inducing peptide. It is a tiny natural molecule, nine amino acids long, first pulled from the blood of sleeping rabbits in 1977 and named because pumping it into the brain made the slow, deep brain waves of deep sleep (called delta waves) grow stronger [1]. Since then people have studied it mostly as a possible sleep aid, and a few small old human studies did report better sleep. But the honest picture is messy: scientists still have not found the receptor it acts on, modern strict trials are basically missing, and a large share of people who try it say it does nothing for them. It is not approved as a medicine anywhere. This site reads the actual studies in plain English, leads with what was really measured, and keeps the gaps in full view. What people report it feels like, the good and the bad, is on the effects page.
What the DSIP literature actually established
Start with the one finding everything else hangs from. In 1977 Schoenenberger and Monnier isolated a nonapeptide (a chain of nine amino acids, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) from the cerebral blood of rabbits in electrically induced sleep, and showed that infusing it directly into the brain produced a significant, specific increase in delta and spindle EEG activity [1]. That is the result that earned the name and it has anchored the field for four decades.
The human signal is real but small. In six middle-aged chronic insomniacs, a single intravenous dose of 25 nmol/kg of synthetic DSIP lengthened sleep, cut interruptions, nudged REM up slightly, and produced no daytime grogginess, with the sleep-promoting effect appearing in the second hour after the injection rather than instantly [2]. A later double-blind study at the same dose found higher sleep efficiency and shorter time-to-sleep than placebo, but its authors called the effect modest and concluded that short-term treatment alone was unlikely to be of major benefit [18].
DSIP reaches the brain by a real route. In the vascularly perfused guinea-pig brain, DSIP crossed the blood-brain barrier (the filter that decides which molecules in the blood get into the brain) through a saturable, high-affinity transport system that L-tryptophan competes with, meaning a specific carrier moves it rather than it simply leaking across [8]. You can follow that thread on the dedicated DSIP half life page.
The riddle at the center: no receptor, no gene, no modern trial
Here is what makes DSIP unusual. After more than forty years, no DSIP receptor, no DSIP gene, and no precursor protein has ever been conclusively identified [3]. A 2006 review in the Journal of Neurochemistry summarized the whole field as a 'still unresolved riddle' and judged the sleep-promotion evidence 'extremely poorly documented and still weak,' noting that synthetic analogs, not native DSIP, often drove the clearest effects [3].
The cross-species story is just as uneven. Rat work showed DSIP raising growth hormone and releasing luteinizing hormone through the hypothalamus [20], yet human studies failed to reproduce several of those neuroendocrine effects, and an early human ACTH-lowering result was not confirmed in later work. The literature even reports a parabolic dose-response, meaning more is not reliably stronger and an intermediate amount can outperform a larger one. None of this makes DSIP a fraud. It makes it a genuine open question, which is exactly how this digest treats it. The full DSIP research survey lays out every finding, gap included.
How to read this site
Every page leads with what was measured and attributes it afterward, the way a clean instrument panel shows the reading first and the source second. Confirmed findings are marked as confirmed; the blank dials, the undiscovered receptor, the missing modern randomized trial, the un-validated human pharmacokinetics, are left openly blank rather than papered over.
The research page is the full scientific survey. The effects page is the honest human layer: what people in research-use communities report, clearly labeled as anecdote, plus the cited safety cautions that actually matter. The half-life page covers how fast the body clears it and how it gets into the brain, and what-is-dsip is the plain-language primer on the delta sleep-inducing peptide. The dosage page reports only what doses were used in which species in published studies; it is not, and never will be, a how-to. Everything quantitative links to a numbered source on the DSIP references page.